Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Casirivimab Imdevimab (Regn-Cov2) Injection
Manufacturer/Marketed By : CIPLA LTD
$1192.96 $954.37
Casirivimab Imdevimab (Regn-COV2) injection contains the active constituent Casirivimab + Imdevimab, a type of protein called monoclonal antibodies. It is used to treat patients with confirmed acute COVID-19 infection. It...
Collapsible text is perfect for longer content like paragraphs and descriptions. It's a great way to give people more information while keeping your layout clean. Link your text to anything, including an external website or a different page. You can set your text box to expand and collapse when people click, so they can read more or less info.
CASIRIVIMAB,IMDEVIMAB
Active Pharmaceutical Ingredient
Casirivimab Imdevimab (Regn-Cov2) Injection
$1,192.96
$954.37
Casirivimab Imdevimab (Regn-COV2) injection contains the active constituent Casirivimab + Imdevimab, a type of protein called monoclonal antibodies. It is used to treat patients with confirmed acute COVID-19 infection. It is also indicated to prevent acute COVID-19 infection. Acute covid-19 infection is caused by a virus called coronavirus. People can get COVID-19 through contact with another person who has the virus. Do not take Casirivimab Imdevimab (Regn-COV2) injection if you are allergic to Casirivimab + Imdevimab or any other ingredients. This medicine can cause allergic reactions following the infusion or injection; notify your physician immediately if you face any of the infusion reactions. Before you take this injection, inform your doctor if you have been vaccinated against COVID infection. Inform your doctor if you are pregnant or breastfeeding before initiating the treatment. The side effects of this Casirivimab Imdevimab (Regn-COV2) injection monoclonal antibody therapy are injection site reactions, fever, flushing, shortness of breath, chest tightness, nausea, and vomiting. If you experience any of these side effects, immediately inform your doctor. This medicine is recommended to use in individuals aged 12 years and older and weighing at least 35.5kg.
Active Pharmaceutical Ingredient
Uses
• Treat and prevent acute COVID-19 infection.
Benefits
Casirivimab Imdevimab (Regn-COV2) injection are two recombinant human monoclonal antibodies that attach to a protein on the surface of the coronavirus called the ‘spike protein.’ This stops the virus from getting into your cells and causing an infection. They block the receptor binding domain (RBD) to the ACE2 receptor and prevent viral attachment to host cells. This can help your body to overcome the virus infection and may help you get better faster.
Side Effects
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them.
Most Common Side Effects
Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles.Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles.Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles.Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles.Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles.
Common Side Effects
• Hypersensitivity reaction
• Infusion reaction
How To Use
Casirivimab Imdevimab (Regn-COV2) injection is given as an infusion into your vein that lasts for 20 to 30 minutes, or it can be given as a subcutaneous (under the skin) injection. This injection will be given to you by a doctor or nurse who is experienced in the use of this type of treatment. They will monitor you closely while you are being given this medicine. Do not self-administer this medicine.
Safety Advice
• Breast Feeding: There is limited information on the safety of Casirivimab Imdevimab (Regn-COV2) injection during breastfeeding. Inform your physician if you are pregnant, suspecting, or planning for pregnancy.
• Alcohol: It is unknown whether it is safe to consume alcohol with Casirivimab Imdevimab (Regn-COV2) injection. Inform your physician if you are a chronic drinker
• Liver: There is limited information available on the use of Casirivimab Imdevimab (Regn-COV2) injection in patients with liver diseases. Inform your physician if you have any liver problems, before initiating the treatment.
• Lungs: It is unknown whether Casirivimab Imdevimab (Regn-COV2) injection can be used in patients with lung disorders. Consult your doctor if you have any lung diseases before starting the treatment.
• Driving: Casirivimab Imdevimab (Regn-COV2) injection does not affect your ability to drive and operate heavy machinery. Inform your physician if you face any symptoms that alter your concentration.
• Pregnancy: There is limited information on the safety of Casirivimab Imdevimab (Regn-COV2) injection during pregnancy. Inform your physician if you are pregnant, suspecting, or planning for pregnancy
Disclaimer
Sidmex Inovia strives to provide accurate and reliable information; however, all content on this website, including product descriptions and compositions, is for informational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment.
Users are advised to consult a qualified healthcare professional before making any medical decisions. The information provided should not be used for self-diagnosis or self-medication.
All products listed are intended strictly for B2B and bulk inquiry purposes only. Sidmex Inovia does not promote direct consumer use and aims to support, not replace, the healthcare professional–patient relationship.
Product names, trademarks, and brands belong to their respective owners, and their use does not imply any affiliation or endorsement. Sidmex Inovia shall not be held responsible for any consequences arising from the use of the information provided on this website.